Relmada Therapeutics (RLMD) Starts Presentation at LD Micro Main Event
Relmada Therapeutics (OTC: RLMD) is a clinical-stage biotech developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of central nervous system (CNS) diseases. The company has a diversified portfolio of four products at various stages of development, including d-Methadone (dextromethadone, REL-1017), an antagonist for depression and neuropathic pain; LevoCap ER (REL-1015), an abuse resistant, sustained release dosage form of the opioid analgesic levorphanol; oral buprenorphine (BuTab, REL-1028), an oral dosage form of the opioid analgesic buprenorphine; and topical mepivacaine (MepiGel, REL-1021), an orphan drug designated…







